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Adjuvant effect of oral Silymarin on patients’ wound 
healing process caused by thermal injuries 
 
 
Abstract 
Background: According to the side effects of the usual treatment of burns, in improving 
the patients’ prognosis, there is a need to introduce faster and more effective adjuvant 
therapies to treat wounds, thus to improve the prognosis of patients. The aim of this study 
was to investigate the effect of adjuvant treatment with oral silymarin on wound healing 
process  caused by second degree-burns among the patients admitted to Valiasr Hospital of 
Arak. 
Methods: This randomized, double-blind clinical trial study was carried out on 80 patients 
with second-degree burns covering 20 to 30 percent of the body with flame. Patients were 
randomized into 2 groups with an equal number: The intervention group (treated daily with 
oral 140-mg silymarin) and control (under the administration of placebo). Patients were 
treated for 8 weeks and at the end of weeks 1, 2, 3 and 4 according to the degree of wound 
healing (grade 1, 2 and 3) were followed during 2016-2017.  
Results: Changes in degrees of burn wound healing in both the intervention and placebo 
groups during the 4 weeks of treatment, significantly improved grade 3 completely. Based 
on the results, the complete remission in all four follow-up stages was significantly higher 
in silymarin group than the placebo group: Week 1 (intervention: 9 (22.5%), control: 0 
(0%), (p=0.011), week 2 (intervention group: 18 (45%), placebo: 7 (17.5%), (p=0.000), 
week 3 (intervention: 24 (60%), placebo: 11 ( 27.5%), (p=0.051); week 4 (intervention: 27 
(67.5%), control: 19 (47.5%), (p=0.003). 
Conclusions: According to our results, the 4-week adjuvant treatment with oral silymarin 
resulted in the full and faster wound recovery in patients with second degree-burn. So, it is 
recommended to use adjuvant treatments to obtain effective results. 
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Burns are the most extreme stress which can happen to the human body. The burn 
wounds can be the result of fires, electrical current, chemicals, boiling fluids, etc. (1). A 
significant number of burn cases are fire-related deaths. The actual percentage of burn is 
not specified at different levels and in different groups of the general population in the 
world, and it seems epidemiology of burns in different countries is influenced by various 
factors and has a different frequency, for example, it was found that the frequency of burns 
in India is higher among young women and in Europe, it is higher among middle-aged 
men than other groups in the general population (2). According to reports, it was found 
that the frequency of flame burns is approximately 3 to 10 percent and the average burn 
surface area in adults is approximately 20 % (1). 
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Now, three local compositions, including silver 
sulfadiazine, mafenide acetate, and silver nitrate are widely 
used to treat burns, but some adverse clinical side effects 
have been observed. So, due to the almost high prevalence of 
burns and to improve the prognosis of patients, it is 
recommended to introduce faster and more effective 
adjuvant therapies to treat burn wounds (1-3). According to 
antioxidant properties and its proper use in wound healing, it 
seems one of the useful drugs in healing burn wound is 
silymarin (silybum marianum extract) (4). 
Silymarin is the most important active ingredient of 
silybum marianum or milk thistle which is composed of a 
group of chemicals called Flavonolignan (5). Silymarin has 
considerable antioxidant property and reduces free radicals 
inhibiting lipid peroxidation (SOD), and increases 
superoxide dismutase activity in the erythrocytes. In 
addition, it has anti-inflammatory effects and causes 
resistance to glutathione depletion and increases protein 
synthesis by hepatocytes during liver parenchymal injuries 
(6, 7).  
In several studies, the efficacy of silymarin in the 
treatment of chronic alcoholic liver disease, cirrhosis, fatty 
liver and viral hepatitis was indicated by assessing the 
metabolic, clinical and histological markers (1, 5); also the 
efficacy of silymarin has been introduced in reducing 
cholesterol and blood sugar levels, anticancer and immune 
regulatory effects (8, 9). In addition to the above, some 
authors have indicated in their animal studies that silymarin 
can be significantly effective in repairing skin wounds due to 
its antioxidant and anti-inflammatory properties (10, 11). 
Although the different properties of silymarin have been 
examined for its effects on various disorders, very limited 
studies have been conducted on the effect of this drug in 
treating burn wounds. Given the need to introduce adjunctive 
therapy in patients with burns to improve the prognosis of 
these patients and consider the anti-inflammatory and 
antioxidant properties of silymarin, this study aimed to 
investigate the effect of adjuvant treatment with oral 
silymarin on wound healing process caused by second 
degree-burns among the patients admitted to Valiasr 
Hospital of Arak. 
 
 
Methods 
In this clinical trial study followed during 2016-2017, 80 
patients aged 18 to 45 years old with second-degree burns on 
20 to 30 percent body surface area due to fire burn, referred 
to the emergency and burn unit of Valiasr Hospital of Arak 
participated after obtaining written consent and according to 
inclusion and exclusion criteria. Exclusion criteria were: 
electrical burns, chemical burns, children and infants, the 
presence of any chronic underlying and systemic disease 
(such as cardiovascular disease, metabolic diseases, 
immunosuppressed (diabetes, transplant), malignancy, 
inflammatory and infectious diseases, etc.), burns and 
trauma, pregnancy, drug addiction, respiratory tract burns, 
patients needing to intubation, patients with a GCS less than 
15, recent history of silymarin consumption or a previous 
allergy and intolerance to oral silymarin, a history of 
malnutrition (malabsorption syndromes for the importance of 
wound healing). Classification of burn was diagnosed based 
on wound depth (5).  
After receiving basic clinical and demographic 
information (age, gender), patients were randomly (chosen 
by tossing the coin) divided into two groups of 40 samples. 
Patients in the intervention group received basic treatment 
and silymarin pill each day; in the control group, basic 
treatment and placebo were administered (with the same 
amount and shape of silymarin tablets produced by Goldaroo 
Company). Initial actions (ABCDE burn patterns, hydration, 
etc.) in dealing with burn patients and basic treatment with 
silver sulfadiazine, silver nitrate, and mafenide acetate were 
performed based on the condition of each patient.  
Wound healing in patients was evaluated at the end of 
weeks 1, 2, 3 and 4 based on clinical responses, for the first 
level: serious wounds, fresh and swollen; second level: 
granulation tissue on the wound; and third level: complete 
epithelial layer on the wounds (healing). At baseline and at 
the end of weeks 1, 2, 3 and 4, the pain was evaluated 
according to the visual analog scale, in which zero represents 
no pain and 10 indicates the unbearable pain (10). It should 
be noted that for as long as the patients are hospitalized, the 
administration and clinical examination was conducted by 
the hospital.  
Executive Assistant when patients were discharged, the 
prescribed drugs were given to patients, and the follow-up 
was performed by calling and visiting the patients back in 
the hospital.  
The data obtained from the examination form and 
demographic data were analyzed using SPSS Version 19 
(SPSS Inc., Chicago, IL). The clinical trial ID registration of 
this research is IRCT2015070923138N1. 
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Results 
In this study 142 patients were enrolled, but after the 
initial examinations, 80 patients remained in two groups with 
40 samples. Among 62 cases excluded from the study, 44 
(70.9%) were not satisfied to enroll in the research and 18 
(29.1%) cases had chronic systemic diseases. 
During the study, 26 patients (10 patients in the placebo 
group and 16 patients in the intervention group) were also 
excluded from the study. Among these 26 cases, 12 (46.1%) 
subjects did not consent to continue to participate in the 
study and were not followed-up, 4 (15.4%) got a wound 
infection, and 10 (38.5%) due to lack of regular drug 
consumption were excluded (figure1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The flowchart of study, inclusion and exclusion 
of patients.  
The average age of all patients was 33.1±5.6 years. The 
average age of the intervention group and placebo was 
33.4±2.1 and 32.8±4.3 years, respectively, which had no 
significant difference (p=0.311). The frequency of male and 
female samples in the two groups were 43 (53.75%) and 37 
(46.25%), respectively. So, there were 22 (55%) males and 
18 (45%) females in the intervention group, and 21 (52.5%) 
males and 19 (47.5%) females in the placebo group. Gender 
distribution of patients was similar in both groups (p=0.2). 
Within 4 weeks and 3 levels of wound healing examinations, 
the changes in silymarin was significant in the first level 
(p=0.000), the second level (p=0.03) and the third level 
(p=0.001).  
Hence, the frequency of the first and the second levels of 
wound healing during 4 weeks significantly reduced and the 
frequency of third level (healing) significantly increased 
(table 1). Changes in the level of wound healing during the 4 
weeks of treatment in the silymarin group are shown in 
figure 2. 
 
Table 1. The frequency of different levels of wound 
healing in patients of silymarin group within 4 weeks 
follow-up stages 
 
Time 
follow-up 
level  
1st  
week 
(40) 
2nd 
week 
(40) 
3rd 
week 
(40) 
4th 
week 
(40) 
P-value 
(Friedman 
test) 
First *  )%(  (67.5)27 (32.5)13 (12.5)5 (0)0 0.000 
Second** 
)%( 
(10)4 (22.5)9 (27.5)11 (32.5)13 0.03 
Third*** 
)%( 
(22.5)9 (45)18 (60)24 (67.5)27 0.001 
* Serious wounds, fresh and swollen; ** granulation tissue on the 
wound; *** complete epithelial layer on the wounds  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The frequency of changes during 4 weeks of 
wound healing in silymarin group  
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In the placebo group, changes in the frequency of first 
level (P=0.005), second level (P=0.041) and third level 
(P=0.021) of wound healing were significant. Consequently, 
the frequency of the first and the second levels of wound 
healing during 4 weeks significantly reduced and the 
frequency of the third level (healing) significantly increased. 
Changes in the level of wound healing during 4 weeks of 
treatment in the placebo group are shown in figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The frequency of changes during 4 weeks of 
wound healing in the placebo group 
Figure 4 shows the cases of complete remission (third 
level) between the intervention and placebo groups. Based 
on the results, the complete remission in all four follow-up 
stages was significantly higher in silymarin group than the 
placebo group: Week 1 (intervention group: 9 (22.5%), 
control: 0 (0%), (P=0.011), week 2 (intervention group: 18 
(45%), placebo: 7 (17.5%), (P=0.000), week 3 (intervention: 
24 (60%), placebo: 11 (27.5%), (P=0.051); week 4 
(intervention: 27 (67.5%), control: 19 (47.5%), (P=0.003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The comparison of the four follow-up stages of 
wound healing in burn patients in both groups of placebo 
and silymarin 
The information about the mean visual analog pain scale 
in 4 follow-up stages and its comparison are shown in figure 
3. Based on the results, the mean visual analog pain scale at 
zero time (the burn) in silymarin and placebo groups were 
9.8±1.2 and 9.5±2.2, respectively. The two groups were 
similar in this regard (P=0.14). The mean visual analog pain 
scale had no significant difference in any of the follow-up 
stages between the two groups (week 1: P=0.112, Week 2: 
P=0.43, Week 3: P=0.124, and week 4: P=0.44). However, 
the changes in the mean visual analog pain scale in both 
silymarin (P=0.001) and placebo (P=0.05) groups during 4 
weeks of treatment significantly decreased (figure 5). Based 
on our results, no drug side effects were reported in the 
consumers of oral silymarin in the intervention group during 
the 4 weeks of treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Changes in the mean visual analog pain scale 
during the 4 weeks of treatment of placebo and silymarin 
groups 
 
Discussion 
According to the present study, the basic treatment with 
oral silymarin for 4 weeks can be effective in healing the 
second-degree burning wounds. Although, adjuvant 
treatment with silymarin leads to a faster full recovery in 
patients with a second-degree burn. Therefore, our study 
showed cases of complete remission at the end of weeks 1, 2, 
3 and 4 in silymarin group was significantly higher than the 
placebo group. Also, the patients’ pain during the 4 weeks of 
treatment and follow-up in both groups significantly 
decreased, and no difference was found between the two 
groups. 
Jahromy et al. in 2011 conducted a study to evaluate the 
effect of silymarin on colon ulcer induced by acetic acid in 
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mice. 32 adult mice in four groups have evaluated the effect 
of oral administration of silymarin 40 and 80 mg on colon 
ulcer. The samples of intervention group received daily 
silymarin 14 days before inducing the disease and then for a 
week after the disease. To induce colitis, 1 ml of 4% acetic 
acid was injected into the rectum. A week after the diagnosis 
of ulcers, a piece of the colon was removed for tissue 
examination and colonic injuries using Moretti’s method. 
Alkaline phosphatase levels were measured by ELISA 
method.  
The amount of tissue edema was also evaluated. The 
results showed that the concentration of alkaline phosphatase 
in the ulcer group was significantly higher than the control 
group and the silymarin group had significantly better-
wound healing and less tissue edema (12) The results of this 
study are consistent with the present study in terms of wound 
healing. Sharifi et al. in 2012 conducted a study on the effect 
of silymarin as a local wound healing in a mouse model. In 
this study, excisional wounds were created in the skin on the 
back of the mice and divided the samples into 3 groups: 
control (no treatment), polyethylene glycol and the treatment 
group (receiving silymarin dissolved in polyethylene glycol) 
and compared them in days 5, 10 and 15 after starting the 
study. The wounds were evaluated in terms of 
histopathology and hydroxyproline level. The results showed 
that silymarin enhances epithelialization and reduces 
inflammation (10). Their results corresponded to ours in 
terms of healing of wounds. 
Although few animal studies have been conducted on the 
effect of silymarin on wound healing (10, 11, 13), still, there 
are few studies on the effect of silymarin improving burn 
wound. Toklu et al. in 2007 performed a study on silymarin 
effect on oxidative damage caused by burns in rats. The 
results of this study showed that the burns caused increased 
levels of TNF-alpha and blood LDH. The MDA and GSH 
levels in skin sample 48 hours after the burns were 
respectively increased and decreased. Based on their results, 
both systemic and local silymarin can significantly reverse 
the high oxidant and antioxidant parameters (5). As well 
local silymarin significantly decreases the increased level of 
MPO activity and CL. Based on the conclusions of this 
study, local and systemic silymarin improves oxidative 
damage caused by burns in a mouse model, as a consequence 
silymarin can be considered as an adjunctive therapy or 
replacement in the burn wounds (14).  
Although our study was different in terms of 
methodology from the mentioned studies, their results were 
consistent with our study in terms of wound healing. Yet 
based on previous studies (15-17) and the present study on 
the impact of silymarin on wound healing, silymarin can be 
effective in improving various wounds and this drug may be 
used as adjunctive therapy in wound healing, but due to the 
lack of human studies, it is necessary to conduct more future 
studies in on different wounds to obtain comprehensive 
conclusion. 
The limitations of this study included; the lack of 
examination of silymarin effect on oxidative factors; the 
deficiency of comparing the effect of local and oral silymarin 
and the unavailability of examination of silymarin effect on 
the infections in burn wound. As a result, future studies are 
recommended to consider these factors to obtain more 
functional conclusions. 
In conclusion based on our findings, standard treatment 
and basic treatment along with oral silymarin for 4 weeks 
can be effective in healing the second-degree burns. 
Nonetheless, adjuvant treatment with silymarin leads to a 
faster complete remission in patients with second-degree 
burn surface. Silymarin can be considered as adjunctive 
therapy for burns’ wound healing. 
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